EC approves Symkevi, Kalydeco combination for cystic fibrosis

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said the European Commission approved Symkevi tezacaftor/ivacaftor in combination with Kalydeco ivacaftor in cystic fibrosis patients 12 and older.

The combination is approved in patients with two copies of the F508del mutation or one copy of the mutation and one copy of 14 other mutations in which cystic fibrosis transmembrane conductance regulator (CFTR) shows residual activity...